Page 68 - MemoriaES-Eng

TRANSVERSAL PLATFORMS

Use of a chemical
compound
derived from a
1,2,3,5-tetrasubstituted CIBERES50%/U. PCT/
08/11/2011 pyrole in the preparation La Laguna 25% /
P201131785
of a drug for use in 29
ES2012/070767 Sistema Canario CIBERES
Abandoned
treating inflammatory 31/10/2012
Salud 25%
diseases involving
processes of cellular
apoptosis

IDIBELL50% / Active.
24/11/2011 Engineered stem cells PCT/
FUVall de Licensed
EP11382362
and their therapeutic use
16
ES2012/070823 Hebron 37,5%/ IDIBELL
to Histocell
23/11/2012
CIBERES12,5%
12/4/2012

CIBERES 66,7%/
11/10/2012 Marker for assessing the FIB Hospital
EP 12382393.2,
risk of developing acute 23
Universitario de CIBERES
Abandoned
kidney injury
Getafe 33,3%

Cyclopentanone
compounds, method for
obtaining them and their CIBERES50%/U.
use in the preparation of La Laguna 16,67% PCT/
31/12/2012 a drug used for treating 29
/Sistema Canario ES2013/070909 CIBERES
Active
P201232075
inflammatory diseases
Salud 16,67%/ 20/12/ 2013
associated with cellular CSIC 16,67%
fibrotic and apoptotic
processes

Inactivated Institut
15/06/2012 mycobacteria for oral germansTries PCT/ Active.
P201200640
use in the prevention of 17
i Pujol (IGTP) ES2013/000145 IGTP
Licensed to
tuberculosis
66,7%/ CIBERES 13/06/2013 Manremyc.
33,3%

Improved bactericidal
28/05/2013 enzybiotics against 34
CSIC 90%/ PCT. Mayo 2014 CSIC
Active
P201330777
pneumococcus and other CIBERES10%
bacteria

10/01/2014 Methods and systems IDIBELL57,5%/
EP14382007
for providing oxygen to 5/ 30
UAB 37,5%/ IDIBELL
Active
a patient
CIBERES 5%

CNIC 40%/CSIC Micellar nanoparticles
17/03/2014 40%/CIBERES CNIC
Active
containing 31
EP14382093
20%
antitumoralglycosides

Managing the transfer to a company.

The PDTT, in collaboration with Parc Tauli, Innovation Unit has conducted 3 new market

studies on CIBERES ideas, and usefull in the search for companies and to present the

product to them.
To improve exposure of our technology offer the transfer section on our web page has

been updated, and a new section dedicated to the CIBERES technology offer has been

created.Thissection currentlypresents10technologyoffersfromCIBERESideas(these 13
documents were drafted by the PDTT for the CIBERES web page and sent to companies 20
T
and include proposals that are co-owned by CIBERES as well as patents belonging to R
PO
CIBERES groups). Specific documents in relation to these offers have also been prepared E
so they can be disseminated in the Europe Enterprise Network (EEN).
L R
A
This documentation has been necessary in order to present the technology to specific NU
N
companies in the area. Companies have been actively sought and contacted as regards A
the product being presented. At least 10 companies have been contacted for each tech- /
ES
nology transfer patent managed by CIBERES PDTT.
ER
B
For the purpose of assuring an operative response in the protection and transfer process, CI

the PDTT has also been responsible for drafting and/or revising and managing non-dis-
closure agreements, collaboration agreements and licensing agreements, among others.
68